[Innovalve in Globes] The heart surgeon with a $300m exit: We had glitches

After several years in which the pharma and digital health companies were seen as the next big thing, a series of deals has demonstrated once more that, in the healthcare sector, medical devices still stand the best chance of making an exit. The acquisition of Innovalve Bio Medical by Edwards Lifesciences (NYSE: EW) for an estimated $300 million is the fourth healthcare exit in Israel since the start of the war, and three of them have been in medical devices.

Read more here.